Launched Phase 2 study of drug known as micro PEA in December 2020
Developing drugs to treat gastrointestinal diseases in dogs and cats
FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201.
The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients.
Known as ultra-micronized PEA, the drug is a naturally occurring fatty acid similar to an endocannabinoid, one of a suite of molecules found in cannabis that targets endocannabinoid (CB2) receptors in the human body. The company holds exclusive worldwide rights to the drug that has been used for 40 years to fight respiratory infections - except in Italy and Spain, where PEA is prescribed as a medical-food supplement to treat chronic infla